PharmaCyte Biotech, Inc. — Form 10-Q Summary
Business context and reporting period. This filing covers the fiscal second quarter and six months ended October 31, 2019. PharmaCyte is a pre-revenue biotechnology company developing Cell-in-a-Box cellular therapies for cancer and diabetes. Its lead program targets locally advanced, inoperable pancreatic cancer; other programs include cannabinoid-based cancer therapies, malignant ascites, and diabetes.
Financial results and liquidity
| Metric | Three months ended October 31 | Six months ended October 31 |
|---|---|---|
| Revenue | $0 in 2019 and 2018 | $0 in 2019 and 2018 |
| Net loss | $1.067 million in 2019; $1.037 million in 2018 | $2.201 million in 2019; $2.252 million in 2018 |
| Operating expenses | $1.067 million in 2019; $1.037 million in 2018 | $2.201 million in 2019; $2.252 million in 2018 |
| Operating cash flow | Not separately presented for the quarter | $(1.347) million in 2019; $(1.540) million in 2018 |
| Cash | — | $45,061 at October 31, 2019, versus $515,253 at April 30, 2019 |
- Costs and margins: With no revenue, the company had no meaningful operating margin. Six-month R&D expense fell to $90,270 from $382,895; compensation, legal and professional, director, and general and administrative expenses together made up most reported costs.
- Balance sheet and liquidity: Current assets were $209,340 against current liabilities of $803,855, a working-capital deficit of approximately $595,000 and a calculated current ratio of about 0.26. Total assets were $5.338 million and total liabilities $803,855. The filing reports no debt balance; liabilities were accounts payable and accrued expenses. A $70,000 non-interest-bearing related-party payable was repaid after quarter-end.
- Cash flows and financing: Six-month investing cash flow was zero; financing provided $883,501, primarily from common-stock sales. Cash declined by $470,192 over the six months. The company reported approximately $950,000 raised from May 1 through August 12, 2019, then ceased using its S-3 after losing eligibility on August 13.
Changes versus the prior comparable period
- Quarterly operating expenses and net loss increased by $30,548 year over year, while six-month operating expenses and net loss decreased by $50,740. The six-month improvement chiefly reflected lower R&D spending; quarterly R&D also declined, but legal and professional costs, compensation, and director fees increased.
- Six-month operating cash use improved by approximately $193,000 year over year, but financing proceeds fell from $1.395 million to $883,501.
- Common shares outstanding rose from 1.186 billion at April 30 to 1.332 billion at October 31. The filing reports 1.392 billion shares outstanding as of December 23, 2019.
Outlook, risks, contingencies and notable items
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern. It has a $102.233 million accumulated deficit, ongoing losses, no biotechnology-sector revenue, and requires substantial additional capital. It planned private placements and said it could reduce consulting and R&D expenses if funding were delayed.
- Subsequent financing: On November 11, 2019, the company agreed to sell 60 million restricted shares for $300,000 in a private placement.
- Development and regulatory outlook: Management was working toward an IND submission to the FDA for a planned Phase 2b pancreatic-cancer trial. The filing gives no firm submission or trial-start date and cautions that FDA acceptance or approval is not assured. Other programs remain in development or preclinical stages.
- Dilution and governance: The company increased authorized common shares to 2.49 billion. A September voting agreement granted certain large holders ten votes per common share. One Series A preferred share issued to the CEO carried voting power equal to all other voting shares plus one; the company redeemed it in December 2019. The filing says these arrangements materially modified common shareholders’ voting power.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective because of material weaknesses involving contract review and control documentation, CFO segregation of duties, and IT controls and documentation. Management was investigating remediation; it warned of risk of material misstatement or restatement.
- Other matters: No material pending legal proceedings were reported. The company has license-related royalty and contingent milestone obligations; amounts may become payable if products are commercialized or development milestones are achieved. The filing provides no numerical earnings or revenue guidance.
Important facts for investors to verify
- Whether the company secured sufficient follow-on financing after the reported $300,000 private placement, and its resulting cash runway.
- Current FDA/IND readiness, trial plans, manufacturing and testing milestones, and the funding required to reach them.
- Progress in remediating the disclosed control weaknesses and any subsequent changes in internal-control conclusions.
- Current shares outstanding, authorized-share capacity, future equity issuance needs, and the practical effects of voting arrangements.
- Potential license royalties, sublicense consideration-sharing terms, and diabetes-program milestone obligations if development advances.